Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Hikma Labs Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions

Early Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Montelukast
Drug: Singulair

First Posted Date: 2012-08-08

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 36

Registration Number: NCT01659892

Locations: 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States

Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions

Early Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Montelukast
Drug: Singulair

First Posted Date: 2012-08-08

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 34

Registration Number: NCT01659931

Locations: 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States

Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions

Early Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Montelukast
Drug: Singulair

First Posted Date: 2012-08-08

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 35

Registration Number: NCT01659918

Locations: 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States

Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions

Early Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Montelukast
Drug: Singulair

First Posted Date: 2012-08-08

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 35

Registration Number: NCT01659905

Locations: 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States

Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions

Phase 1

Completed

Conditions: Trichomoniasis

Interventions: Drug: Tinidazole

First Posted Date: 2012-05-04

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 28

Registration Number: NCT01591889

Locations: 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions

Not Applicable

Completed

Conditions: Treatment for Bipolar I Disorder

First Posted Date: 2012-04-04

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 42

Registration Number: NCT01570907

Locations: 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions

Not Applicable

Completed

Conditions: Bipolar I Disorder

First Posted Date: 2012-04-04

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 42

Registration Number: NCT01570894

Locations: 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States

Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions

Not Applicable

Completed

Conditions: Bipolar I Disorder

First Posted Date: 2012-04-04

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 56

Registration Number: NCT01570959

Locations: 🇺🇸
Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
🇺🇸
Synergy Clinical Research Center, National City, California, United States
🇺🇸
Segal Institute for Clinical Research, North Miami, Florida, United States

and more 4 locations

Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: letrozole

First Posted Date: 2011-06-07

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 28

Registration Number: NCT01367626

Locations: 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States

Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Letrozole

First Posted Date: 2011-06-07

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 28

Registration Number: NCT01367652

Locations: 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy